Home › All Companies › ARMP › Insider Trading

Armata Pharmaceuticals, Inc. (ARMP) — Insider Trading

AI-Powered SEC Filing Analysis

← All ARMP filings
Latest Insider Trading Filed: 2026-04-28

Key Insights

  • Director Daniel Gilmer received a grant of 51,280 stock options with an exercise price of $12.92, vesting in equal thirds over three years, indicating company confidence in future performance and aligning insider interests with shareholders.
  • The option grant was dated 04/24/2026 with a 10-year expiration (04/24/2036), representing standard equity compensation practices for board members with meaningful potential value at higher stock prices.
  • This is a routine equity grant with no indication of insider selling or portfolio rebalancing, which is neutral to slightly positive as it demonstrates retained confidence in the company by a board member.
Sentiment: Neutral Significance: 2/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Armata Pharmaceuticals, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.